<DOC>
	<DOCNO>NCT02996318</DOCNO>
	<brief_summary>The aim study investigate non-inferiority new sirolimus-coated balloon catheter comparison paclitaxel-coated SQP regard acute tolerance , safety efficacy coronary DES in-stent restenosis .</brief_summary>
	<brief_title>Treatment Coronary In-Stent Restenosis Sirolimus ( Rapamycin ) Coated Balloon Paclitaxel Coated Balloon</brief_title>
	<detailed_description>The aim study investigate non-inferiority new sirolimus-coated balloon catheter comparison paclitaxel-coated SQP regard acute tolerance , safety efficacy coronary DES in-stent restenosis . Patient population consist male female adult suffer coronary drug-eluting stent ( DES ) restenosis , treat study balloon accord inclusion exclusion criterion define . In Late lumen loss lesion ( difference angiographic in-lesion MLD post procedural 6 month follow-up ) evaluate quantitative coronary angiography ( QCA ) . The study perform single-blind , SQP control study 4 - 6 study center 50 patient .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>18 year age Clinical evidence stable unstable angina ( acute coronary syndrome ) positive functional study Patients ≤ 2 primary drugeluting stent instent restenosis ( DESISR ) lesion ( ≥ 70 % diameter stenosis visual estimation ≥ 50 % positive functional study ) include margin stenosis max 5mm distance stent . Chronic renal insufficiency serum creatinine level &gt; 2.0 mg per deciliter Known hypersensitivity contraindication aspirin , heparin , clopidogrel , ticlopidine sirolimus , sensitivity contrast medium amenable premedication Concomitant medical illness associate lifeexpectancy less two year Lesion length ( ISR ) &gt; 35 mm , vessel diameter &lt; 2.5 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>